77/100BIf you had invested in Alcon ago, it would be worth $1,305 today, against $2,646 in SPY and $3,428 in QQQ.
Arincen ScoreBeta
Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.
Profitability4
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Cash10
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Valuation10
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Growth10
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Financial strength4
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Shareholders8
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Figures to FY2025; the price as of today.
Alcon key facts
- Style
- Blend stock · 5.3/10Growth 5.3 · Value 3.3 · Dividend 1.0
- Day range
- 74.040 – 75.230
- 52-week range
- 61.835 – 87.640
- Market capitalization
- 36.22B USD
- P/E
- 57.64
- PEG ratio
- 2.38
- EPS
- 1.30
- Div Yield
- 0.48%
- EPS growth forecast (FY2026)
- +14.5%
- Volume
- 111,282
- Beta
- 0.73
- Sector
- Healthcare
- Industry
- Medical - Specialties
- CEO
- David J. Endicott
- Employees
- 25K
- Website
- alcon.com
- IPO date
- 9 Apr 2019
Alcon earnings
Revenue
EPS
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q4 FY2026 | 0.94 | — | — | +20.58% | 2.84B | — | — | +7.90% | |
| Q3 FY2026 | 0.89 | — | — | +12.66% | 2.68B | — | — | +2.68% | |
| Q2 FY2026 | 0.77 | 0.84 | +9.09% | +10.53% | 2.72B | 2.79B | +2.54% | +7.48% | |
| Q1 FY2026 | 0.80 | 0.85 | +6.25% | +16.44% | 2.64B | 2.65B | +0.42% | +7.30% | |
| Q4 FY2025 | 0.79 | 0.78 | -1.27% | +8.33% | 2.69B | 2.64B | -1.87% | +5.35% | |
| Q3 FY2025 | 0.77 | 0.79 | +2.60% | -2.47% | 2.71B | 2.61B | -3.58% | +6.52% | |
| Q2 FY2025 | 0.71 | 0.76 | +7.04% | +2.70% | 2.65B | 2.60B | -2.06% | +3.38% | |
| Q1 FY2025 | 0.76 | 0.73 | -3.95% | -6.41% | 2.63B | 2.47B | -5.84% | +0.57% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | 4.46 | — | — | +12.87% | 12.42B | — | — | +6.01% |
| FY2027 | 3.96 | — | — | +12.91% | 11.72B | — | — | +5.81% |
| FY2026 | 3.50 | — | — | +14.50% | 11.07B | — | — | +7.31% |
| FY2025 | 3.06 | 3.06 | -0.07% | +0.33% | 10.26B | 10.32B | +0.54% | +3.96% |
| FY2024 | 2.99 | 3.05 | +1.93% | +11.31% | 9.76B | 9.93B | +1.67% | +3.60% |
| FY2023 | 2.81 | 2.74 | -2.45% | +22.87% | 9.71B | 9.58B | -1.29% | +9.92% |
| FY2022 | 2.27 | 2.23 | -1.61% | +3.72% | 8.75B | 8.72B | -0.42% | +5.14% |
Alcon analyst forecast
Analysts' 1-year price targets range from 35.00 to 98.00, with an average of 77.22.
| Strong buy | 0 | |
| Buy | 7 | |
| Hold | 3 | |
| Sell | 1 | |
| Strong sell | 0 |
12-month price target
| Highest target | 98.00 |
| Average target | 77.22 |
| Lowest target | 35.00 |
| Current price | 74.93 |
Alcon valuation
- Price to earnings ratio (TTM)
- 57.64
- Forward P/E (FY2026)
- 21.39
- Price to sales (TTM)
- 3.35
- Price to book
- 1.68
- EV / EBITDA (TTM)
- 14.47
Capital structure
Valuation over time
Alcon against its own history
Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: Centene, GE HealthCare Technologies, Biogen, Revolution Medicines, Medline, and Zoetis, the US Healthcare companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- P/E (today)Below its median57.635.7131.3
- Gross marginBelow its median55.2%54.5%56.1%Against its peers: 4 of 7Peers' median 55.2%
- Operating marginAbove its median13.1%7.0%14.3%Against its peers: 4 of 7Peers' median 10.6%
- Net marginAt its median9.4%3.8%10.3%Against its peers: 4 of 7Peers' median 7.1%
- Return on equityAt its median4.4%1.7%4.7%Against its peers: 5 of 7Peers' median 8.9%
- Free cash flow marginHighest in 5 years15.5%2.0%15.5%Against its peers: 3 of 7Peers' median 5.9%
- Revenue growthBelow its median4.9%4.8%21.3%Against its peers: 3 of 7Peers' median 3.6%
- EPS growthBelow its median-3.4%-10.5%188.2%Against its peers: 3 of 6Peers' median -5.9%
- Debt to EBITDABelow its median2.10×1.92×2.91×Against its peers: 1 of 5Peers' median 2.50×
- Current ratioBelow its median2.121.902.77Against its peers: 5 of 7Peers' median 2.85
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
Alcon growth and profitability
- Revenue (TTM)
- 10.81B USD
- Net income (TTM)
- 639.33M USD
- Gross margin
- 56.45%
- Operating margin
- 9.87%
- Net margin
- 5.92%
Revenue / Net income
Alcon revenue breakdown
By region
| Region | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| International Geographic Areas | 5.66B | 35.4% | +6.3% |
| United States | 4.66B | 29.1% | +3.2% |
| Other Countries | 4.41B | 27.6% | +6.8% |
| Japan | 609.00M | 3.8% | +9.9% |
| China | 570.00M | 3.6% | +1.8% |
| Switzerland | 71.00M | 0.4% | -10.1% |
How Alcon makes its money
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
Alcon dividends
- Annual dividend
- 0.36 USD
- Dividend yield (indicated)
- 0.48%
- Payout ratio
- 27.64%
- Years of dividend growth
- 5
- Frequency
- Annual
- Last payment
- 0.36 USD
- Last ex-dividend date
- 6 May 2026
- Last payment date
- 7 May 2026
Dividends per share
Alcon financial health
- Cash and short-term investments
- 1.46B USD
- Total debt
- 5.30B USD
- Net cash
- -3.84B USD
- Free cash flow (TTM)
- 1.68B USD
- Current ratio
- 2.09
- Debt to equity
- 0.25
- Piotroski score
- 8 / 9
- Altman Z-score
- 2.95
Cash, debt and free cash flow
Alcon ownership
- Institutions
- 49.42%
- Institutional holders
- 671 (-19)
- Free float
- 99.68%
Who owns the shares
Shares free to trade
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Shares outstanding
Source: Financial Modeling Prep